25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aytu BioScience Inc
Buy, Hold or Sell?

Let's analyze Aytu BioScience Inc together

I guess you are interested in Aytu BioScience Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aytu BioScience Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aytu BioScience Inc

I send you an email if I find something interesting about Aytu BioScience Inc.

1. Quick Overview

1.1. Quick analysis of Aytu BioScience Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aytu BioScience Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$3.28
Expected worth in 1 year
$1.32
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
$-1.95
Return On Investment
-135.6%

For what price can you sell your share?

Current Price per Share
$1.44
Expected price per share
$1.38 - $2.23
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aytu BioScience Inc (5 min.)




Live pricePrice per Share (EOD)
$1.44
Intrinsic Value Per Share
$-20.52 - $11.25
Total Value Per Share
$-17.25 - $14.52

2.2. Growth of Aytu BioScience Inc (5 min.)




Is Aytu BioScience Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$29.8m$39.5m-$9.2m-30.6%

How much money is Aytu BioScience Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$6.7m$5.1m328.7%
Net Profit Margin-8.5%-27.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Aytu BioScience Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aytu BioScience Inc?

Welcome investor! Aytu BioScience Inc's management wants to use your money to grow the business. In return you get a share of Aytu BioScience Inc.

First you should know what it really means to hold a share of Aytu BioScience Inc. And how you can make/lose money.

Speculation

The Price per Share of Aytu BioScience Inc is $1.44. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aytu BioScience Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aytu BioScience Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.28. Based on the TTM, the Book Value Change Per Share is $-0.49 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.88 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aytu BioScience Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.1611.2%-0.27-19.0%-0.80-55.7%-1.68-116.6%-1.34-93.3%
Usd Book Value Change Per Share-1.23-85.4%-0.49-33.9%-0.88-61.4%0.1410.1%0.085.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.23-85.4%-0.49-33.9%-0.88-61.4%0.1410.1%0.085.7%
Usd Price Per Share2.35-2.79-1.68-2.39-1.75-
Price to Earnings Ratio3.63--4.70--0.74--1.63--0.98-
Price-to-Total Gains Ratio-1.91-2.17--2.90--0.30--0.40-
Price to Book Ratio0.72-0.63-0.28-0.28-0.68-
Price-to-Total Gains Ratio-1.91-2.17--2.90--0.30--0.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.44
Number of shares694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.490.14
Usd Total Gains Per Share-0.490.14
Gains per Quarter (694 shares)-338.88100.62
Gains per Year (694 shares)-1,355.53402.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1356-13660402392
20-2711-27220805794
30-4067-4078012071196
40-5422-5434016101598
50-6778-6790020122000
60-8133-8146024152402
70-9489-9502028172804
80-10844-10858032203206
90-12200-12214036223608
100-13555-13570040254010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%2.069.00.02.8%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%7.012.01.035.0%17.022.01.042.5%22.045.04.031.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.070.01.4%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%7.012.01.035.0%17.022.01.042.5%22.045.04.031.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aytu BioScience Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.229-0.488-60%-0.884-28%0.145-948%0.082-1597%
Book Value Per Share--3.2784.533-28%6.434-49%10.848-70%6.211-47%
Current Ratio--0.9920.987+0%1.026-3%1.346-26%1.952-49%
Debt To Asset Ratio--0.7430.755-2%0.717+4%0.607+22%0.692+7%
Debt To Equity Ratio--2.8843.082-6%2.571+12%1.902+52%2.339+23%
Dividend Per Share----0%-0%-0%0.000-100%
Enterprise Value---44512937.650-54491120.413+22%-74931876.052+68%-47623546.954+7%-26178012.702-41%
Eps--0.162-0.274+269%-0.802+595%-1.679+1136%-1.344+930%
Ev To Ebitda Ratio---2.8403.420-183%inf+inf%inf+inf%inf+inf%
Ev To Sales Ratio---0.671-0.725+8%-0.739+10%-0.676+1%-0.044-93%
Free Cash Flow Per Share---0.146-0.084-42%0.155-194%-0.729+401%-0.615+322%
Free Cash Flow To Equity Per Share---0.0460.001-7810%-0.147+222%0.140-133%0.177-126%
Gross Profit Margin---2.8398.427-134%2.031-240%3.142-190%2.104-235%
Intrinsic Value_10Y_max--11.247--------
Intrinsic Value_10Y_min---20.523--------
Intrinsic Value_1Y_max---1.343--------
Intrinsic Value_1Y_min---2.407--------
Intrinsic Value_3Y_max---2.152--------
Intrinsic Value_3Y_min---6.971--------
Intrinsic Value_5Y_max---0.693--------
Intrinsic Value_5Y_min---11.215--------
Market Cap8855092.800-141%21384062.35018874629.588+13%10344623.948+107%15024091.446+42%10958982.836+95%
Net Profit Margin--0.089-0.085+195%-0.275+409%-0.751+944%-4.945+5661%
Operating Margin--0.150-0.084+156%-0.161+207%-0.307+304%-2.020+1444%
Operating Ratio--0.9531.012-6%1.220-22%1.399-32%8.822-89%
Pb Ratio0.439-63%0.7170.626+15%0.282+154%0.280+156%0.683+5%
Pe Ratio2.222-63%3.627-4.702+230%-0.739+120%-1.633+145%-0.975+127%
Price Per Share1.440-63%2.3502.788-16%1.682+40%2.387-2%1.754+34%
Price To Free Cash Flow Ratio-2.470+39%-4.032-15.117+275%-5.178+28%-4.464+11%-2.477-39%
Price To Total Gains Ratio-1.171+39%-1.9112.169-188%-2.897+52%-0.300-84%-0.403-79%
Quick Ratio--0.7060.691+2%0.619+14%0.949-26%1.579-55%
Return On Assets--0.013-0.013+199%-0.048+478%-0.093+828%-0.182+1532%
Return On Equity--0.049-0.054+210%-0.171+446%-0.250+606%-0.513+1138%
Total Gains Per Share---1.229-0.488-60%-0.884-28%0.145-948%0.082-1595%
Usd Book Value--29826000.00030293000.000-2%39563250.000-25%67191891.450-56%38436739.400-22%
Usd Book Value Change Per Share---1.229-0.488-60%-0.884-28%0.145-948%0.082-1597%
Usd Book Value Per Share--3.2784.533-28%6.434-49%10.848-70%6.211-47%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Enterprise Value---44512937.650-54491120.413+22%-74931876.052+68%-47623546.954+7%-26178012.702-41%
Usd Eps--0.162-0.274+269%-0.802+595%-1.679+1136%-1.344+930%
Usd Free Cash Flow---1326000.000-625750.000-53%952000.000-239%-4507340.650+240%-3792575.300+186%
Usd Free Cash Flow Per Share---0.146-0.084-42%0.155-194%-0.729+401%-0.615+322%
Usd Free Cash Flow To Equity Per Share---0.0460.001-7810%-0.147+222%0.140-133%0.177-126%
Usd Market Cap8855092.800-141%21384062.35018874629.588+13%10344623.948+107%15024091.446+42%10958982.836+95%
Usd Price Per Share1.440-63%2.3502.788-16%1.682+40%2.387-2%1.754+34%
Usd Profit--1474000.000-1563250.000+206%-6702250.000+555%-16041241.550+1188%-10351625.250+802%
Usd Revenue--16574000.00018869250.000-12%25460750.000-35%19740420.750-16%10331043.475+60%
Usd Total Gains Per Share---1.229-0.488-60%-0.884-28%0.145-948%0.082-1595%
 EOD+4 -4MRQTTM+18 -20YOY+19 -195Y+18 -2010Y+17 -23

3.3 Fundamental Score

Let's check the fundamental score of Aytu BioScience Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-152.222
Price to Book Ratio (EOD)Between0-10.439
Net Profit Margin (MRQ)Greater than00.089
Operating Margin (MRQ)Greater than00.150
Quick Ratio (MRQ)Greater than10.706
Current Ratio (MRQ)Greater than10.992
Debt to Asset Ratio (MRQ)Less than10.743
Debt to Equity Ratio (MRQ)Less than12.884
Return on Equity (MRQ)Greater than0.150.049
Return on Assets (MRQ)Greater than0.050.013
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Aytu BioScience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.599
Ma 20Greater thanMa 501.582
Ma 50Greater thanMa 1001.869
Ma 100Greater thanMa 2002.184
OpenGreater thanClose1.500
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Aytu BioScience Inc

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Fundamental data was last updated by Penke on 2024-12-05 13:30:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aytu BioScience Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 8.9% means that $0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aytu BioScience Inc:

  • The MRQ is 8.9%. The company is making a profit. +1
  • The TTM is -8.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ8.9%TTM-8.5%+17.3%
TTM-8.5%YOY-27.5%+19.0%
TTM-8.5%5Y-75.1%+66.6%
5Y-75.1%10Y-494.5%+419.5%
4.3.1.2. Return on Assets

Shows how efficient Aytu BioScience Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.3% Return on Assets means that Aytu BioScience Inc generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aytu BioScience Inc:

  • The MRQ is 1.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is -1.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.3%TTM-1.3%+2.5%
TTM-1.3%YOY-4.8%+3.5%
TTM-1.3%5Y-9.3%+8.0%
5Y-9.3%10Y-18.2%+9.0%
4.3.1.3. Return on Equity

Shows how efficient Aytu BioScience Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.9% Return on Equity means Aytu BioScience Inc generated $0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aytu BioScience Inc:

  • The MRQ is 4.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -5.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.9%TTM-5.4%+10.4%
TTM-5.4%YOY-17.1%+11.7%
TTM-5.4%5Y-25.0%+19.6%
5Y-25.0%10Y-51.3%+26.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aytu BioScience Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aytu BioScience Inc is operating .

  • Measures how much profit Aytu BioScience Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 15.0% means the company generated $0.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aytu BioScience Inc:

  • The MRQ is 15.0%. The company is operating efficient. +1
  • The TTM is -8.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ15.0%TTM-8.4%+23.4%
TTM-8.4%YOY-16.1%+7.8%
TTM-8.4%5Y-30.7%+22.3%
5Y-30.7%10Y-202.0%+171.3%
4.3.2.2. Operating Ratio

Measures how efficient Aytu BioScience Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are $0.95 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.953. The company is less efficient in keeping operating costs low.
  • The TTM is 1.012. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.953TTM1.012-0.059
TTM1.012YOY1.220-0.209
TTM1.0125Y1.399-0.387
5Y1.39910Y8.822-7.423
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aytu BioScience Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.99 means the company has $0.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.992. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.987. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.992TTM0.987+0.005
TTM0.987YOY1.026-0.039
TTM0.9875Y1.346-0.359
5Y1.34610Y1.952-0.606
4.4.3.2. Quick Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.71 means the company can pay off $0.71 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.706. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.691. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.706TTM0.691+0.016
TTM0.691YOY0.619+0.072
TTM0.6915Y0.949-0.258
5Y0.94910Y1.579-0.630
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aytu BioScience Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aytu BioScience Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aytu BioScience Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.74 means that Aytu BioScience Inc assets are financed with 74.3% credit (debt) and the remaining percentage (100% - 74.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.743. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.755. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.743TTM0.755-0.012
TTM0.755YOY0.717+0.038
TTM0.7555Y0.607+0.148
5Y0.60710Y0.692-0.086
4.5.4.2. Debt to Equity Ratio

Measures if Aytu BioScience Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 288.4% means that company has $2.88 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aytu BioScience Inc:

  • The MRQ is 2.884. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.082. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.884TTM3.082-0.198
TTM3.082YOY2.571+0.511
TTM3.0825Y1.902+1.180
5Y1.90210Y2.339-0.437
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aytu BioScience Inc generates.

  • Above 15 is considered overpriced but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 3.63 means the investor is paying $3.63 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aytu BioScience Inc:

  • The EOD is 2.222. Based on the earnings, the company is cheap. +2
  • The MRQ is 3.627. Based on the earnings, the company is cheap. +2
  • The TTM is -4.702. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.222MRQ3.627-1.404
MRQ3.627TTM-4.702+8.329
TTM-4.702YOY-0.739-3.963
TTM-4.7025Y-1.633-3.069
5Y-1.63310Y-0.975-0.657
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aytu BioScience Inc:

  • The EOD is -2.470. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.032. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.117. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.470MRQ-4.032+1.561
MRQ-4.032TTM-15.117+11.086
TTM-15.117YOY-5.178-9.939
TTM-15.1175Y-4.464-10.653
5Y-4.46410Y-2.477-1.987
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aytu BioScience Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Aytu BioScience Inc:

  • The EOD is 0.439. Based on the equity, the company is cheap. +2
  • The MRQ is 0.717. Based on the equity, the company is cheap. +2
  • The TTM is 0.626. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.439MRQ0.717-0.278
MRQ0.717TTM0.626+0.091
TTM0.626YOY0.282+0.344
TTM0.6265Y0.280+0.346
5Y0.28010Y0.683-0.404
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aytu BioScience Inc.

4.8.1. Institutions holding Aytu BioScience Inc

Institutions are holding 34.038% of the shares of Aytu BioScience Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Nantahala Capital Management, LLC17.67360.12921086812-1086812-50
2024-09-30Stonepine Capital Management Llc8.14650.7439500958284896.0298
2024-09-30Armistice Capital, LLC3.83780.0089236000-16000-6.3492
2024-09-30Renaissance Technologies Corp1.21510.0003747236000.8095
2024-09-30Geode Capital Management, LLC0.7334045102918325.5659
2024-09-30Vanguard Group Inc0.453502788800
2024-06-30BlackRock Inc0.370702279300
2024-09-30Dimensional Fund Advisors, Inc.0.355021832-1719-7.2991
2024-09-30Northern Trust Corp0.236701455700
2024-09-30Tower Research Capital LLC0.0240.00011473-489-24.9235
2024-09-30JPMorgan Chase & Co0.00510313-227-42.037
2024-06-30Advisor Group Holdings, Inc.0.0049030000
2024-09-30Morgan Stanley - Brokerage Accounts0.00470290-590-67.0455
2024-09-30UBS Group AG0.00420260-48-15.5844
2024-09-30Wells Fargo & Co0.002012400
2024-06-30Bank of America Corp0.00150924284
2024-06-30Atlantic Trust Group, LLC0.001308300
2024-09-30Group One Trading, LP0.000603700
2024-09-30Goss Wealth Management LLC0.000302100
2024-06-30U.S. Bancorp0.00010990
Total 33.0710.88242033667-1067562-52.5%

4.9.2. Funds holding Aytu BioScience Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Fidelity Extended Market Index0.55320.000234019411913.7759
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.45350.00012788800
2024-09-30DFA US Targeted Value I0.14090.00028664250440.6494
2024-09-30Fidelity Series Total Market Index0.131080544944158.9711
2024-09-30NT Ext Equity Mkt Idx Fd - L0.10260.0002631100
2024-09-30Northern Trust Extended Eq Market Idx0.10260.0002631100
2024-11-28Dimensional US Sustainability Core 1 ETF0.06260.0005384700
2024-09-30BlackRock Extended Equity Market K0.05790.00013558-2-0.0562
2024-11-28Dimensional US Targeted Value ETF0.05490.0001337800
2024-09-30DFA US Micro Cap I0.05250.0001322800
2024-08-31DFA US Core Equity Class F0.04650.0002286200
2024-09-30Fidelity Total Market Index0.02580158900
2024-09-30Bridgeway Omni Small-Cap Value0.02440.0003150000
2024-09-30Bridgeway Omni Small-Cap Value N0.02440.0003150000
2024-09-30DFA US Social Core Equity 2 Portfolio0.0240.0002147400
2024-09-30Spartan Extended Market Index Pool E0.02280.000114051209.3385
2024-10-31Dimensional US Core Equity USD Acc0.02170.0008133600
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.02040125200
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.01640100930.2982
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01580.000297420.2058
Total 1.95390.0038120159+11690+9.7%

5.3. Insider Transactions

Insiders are holding 2.437% of the shares of Aytu BioScience Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-16Greg PyszczymukaBUY120001.87
2023-06-14Joshua R DisbrowBUY140001.86
2022-12-19Greg PyszczymukaBUY1000000.24
2022-12-19Joshua R DisbrowBUY1123710.22
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Income  -8,1207,900-220-2,670-2,890-1,727-4,6176,0911,474
Total Other Income Expense Net -6,6164,860-1,7561,578-178-94-2722,7002,428
Net Income from Continuing Operations  -8,1207,900-220-2,667-2,887-1,730-4,6175,7101,093



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets115,831
Total Liabilities86,005
Total Stockholder Equity29,826
 As reported
Total Liabilities 86,005
Total Stockholder Equity+ 29,826
Total Assets = 115,831

Assets

Total Assets115,831
Total Current Assets60,738
Long-term Assets55,093
Total Current Assets
Cash And Cash Equivalents 20,108
Net Receivables 23,159
Inventory 11,739
Other Current Assets 5,732
Total Current Assets  (as reported)60,738
Total Current Assets  (calculated)60,738
+/-0
Long-term Assets
Property Plant Equipment 1,917
Intangible Assets 51,205
Long-term Assets Other 1,971
Long-term Assets  (as reported)55,093
Long-term Assets  (calculated)55,093
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities61,252
Long-term Liabilities24,753
Total Stockholder Equity29,826
Total Current Liabilities
Short-term Debt 6,127
Short Long Term Debt 6,127
Accounts payable 13,513
Other Current Liabilities 41,612
Total Current Liabilities  (as reported)61,252
Total Current Liabilities  (calculated)67,379
+/- 6,127
Long-term Liabilities
Long term Debt 10,430
Long-term Liabilities Other 4,921
Long-term Liabilities  (as reported)24,753
Long-term Liabilities  (calculated)15,351
+/- 9,402
Total Stockholder Equity
Common Stock1
Retained Earnings -318,499
Other Stockholders Equity 348,324
Total Stockholder Equity (as reported)29,826
Total Stockholder Equity (calculated)29,826
+/-0
Other
Capital Stock1
Cash and Short Term Investments 20,108
Common Stock Shares Outstanding 9,100
Liabilities and Stockholders Equity 115,831
Net Debt -3,551
Net Invested Capital 46,383
Net Working Capital -514
Property Plant and Equipment Gross 3,782
Short Long Term Debt Total 16,557



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-03-31
> Total Assets 
68
68
68
68
68
60
108
95
82
74
53
43
43
42
30
26
36
27
25
28
28
23
16
16
13
13
12
13
9
10
7
6
13
6
11
10,201
18,227
21,359
24,410
21,986
24,343
20,201
21,506
15,917
14,999
21,246
18,858
23,375
21,060
17,985
42,399
38,338
34,721
31,024
74,478
158,954
152,836
152,836
166,742
271,557
265,668
227,729
223,824
168,826
137,623
150,000
141,436
147,216
136,463
132,888
131,249
128,863
118,095
115,831
115,831118,095128,863131,249132,888136,463147,216141,436150,000137,623168,826223,824227,729265,668271,557166,742152,836152,836158,95474,47831,02434,72138,33842,39917,98521,06023,37518,85821,24614,99915,91721,50620,20124,34321,98624,41021,35918,22710,2011161367109131213131616232828252736263042434353748295108606868686868
   > Total Current Assets 
0
0
0
30
30
23
69
58
44
38
18
10
13
14
4
1
8
2
1
6
8
4
1
1
0
0
1
3
1
2
1
0
9
2
9
1,650
8,084
11,308
12,765
10,437
10,120
6,364
8,158
4,438
3,029
9,742
7,745
14,595
9,470
6,872
21,977
18,459
15,433
11,983
18,338
83,255
74,966
74,966
92,537
100,013
105,234
89,038
87,540
77,947
59,929
74,415
70,611
78,465
72,832
70,599
71,371
71,130
61,891
60,738
60,73861,89171,13071,37170,59972,83278,46570,61174,41559,92977,94787,54089,038105,234100,01392,53774,96674,96683,25518,33811,98315,43318,45921,9776,8729,47014,5957,7459,7423,0294,4388,1586,36410,12010,43712,76511,3088,0841,6509290121310011486128141413101838445869233030000
       Cash And Cash Equivalents 
0
0
0
29
29
23
69
58
44
38
18
10
13
14
3
0
8
2
1
6
7
4
1
1
0
0
1
3
1
2
0
0
9
2
9
1,491
7,353
10,069
10,960
8,666
8,054
2,749
5,230
3,470
802
7,022
3,908
12,006
7,013
3,965
17,805
14,647
11,044
7,014
5,259
62,265
48,082
48,082
62,033
46,538
49,649
40,308
35,277
27,613
19,360
23,811
19,501
19,179
22,985
19,964
19,529
19,760
20,006
20,108
20,10820,00619,76019,52919,96422,98519,17919,50123,81119,36027,61335,27740,30849,64946,53862,03348,08248,08262,2655,2597,01411,04414,64717,8053,9657,01312,0063,9087,0228023,4705,2302,7498,0548,66610,96010,0697,3531,4919290021310011476128031413101838445869232929000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,279
0
0
0
0
0
0
1,041
1,769
1,272
75
75
75
76
76
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000010010076767575751,2721,7691,0410000005,279000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
157
168
288
84
162
509
582
343
528
1,212
1,377
732
579
760
1,482
1,376
1,741
2,705
6,547
10,203
5,176
5,176
7,001
28,228
28,176
21,626
22,989
27,613
21,712
27,924
25,547
34,043
28,937
29,882
29,403
29,925
23,617
23,159
23,15923,61729,92529,40329,88228,93734,04325,54727,92421,71227,61322,98921,62628,17628,2287,0015,1765,17610,2036,5472,7051,7411,3761,4827605797321,3771,21252834358250916284288168157110000000000000110000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147
7
534
577
864
1,065
338
750
634
417
386
337
1,079
973
540
837
1,045
905
1,208
59
1,427
1,850
11,709
5,742
10,599
1,615
1,038
1,195
1,418
888
633
785
624
1,177
868
749
9,438
8,252
5,635
5,732
5,7325,6358,2529,4387498681,1776247856338881,4181,1951,0381,61510,5995,74211,7091,8501,427591,2089051,0458375409731,0793373864176347503381,06586457753471470000000000000000000000000000000000
   > Long-term Assets 
0
0
0
38
38
36
38
37
38
36
35
32
30
28
26
25
28
25
24
22
20
19
15
15
0
12
11
10
9
8
7
5
4
3
2
8,551
10,143
10,052
11,645
11,549
14,223
13,837
13,348
11,478
11,970
11,504
11,114
8,780
11,590
11,113
20,422
19,879
19,289
19,041
56,140
75,699
77,871
77,871
74,205
171,544
160,434
138,691
136,284
90,879
77,694
75,585
70,825
68,751
63,631
62,289
59,878
57,733
56,204
55,093
55,09356,20457,73359,87862,28963,63168,75170,82575,58577,69490,879136,284138,691160,434171,54474,20577,87177,87175,69956,14019,04119,28919,87920,42211,11311,5908,78011,11411,50411,97011,47813,34813,83714,22311,54911,64510,05210,1438,55123457891011120151519202224252825262830323536383738363838000
       Property Plant Equipment 
0
0
0
38
38
36
38
37
38
36
35
32
30
28
26
25
28
25
24
22
20
19
15
15
12
12
11
10
8
8
6
5
4
3
2
37
30
26
144
197
231
313
292
271
647
567
561
261
219
196
187
219
204
532
497
964
259
893
400
9,340
8,703
8,492
8,139
7,040
6,296
5,648
5,019
4,395
3,869
4,176
3,260
2,762
1,522
1,917
1,9171,5222,7623,2604,1763,8694,3955,0195,6486,2967,0408,1398,4928,7039,340400893259964497532204219187196219261561567647271292313231197144263037234568810111212151519202224252825262830323536383738363838000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
221
221
221
221
221
74
238
238
238
0
0
0
0
0
0
0
15,387
24,061
28,090
28,090
28,090
65,803
65,802
46,349
46,349
8,637
0
0
0
0
0
0
0
0
0
0
00000000008,63746,34946,34965,80265,80328,09028,09028,09024,06115,3870000000238238238742212212212212217474000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,200
0
8,146
8,146
9,699
9,641
11,003
10,885
13,554
13,117
12,680
11,131
11,081
10,696
10,312
8,516
11,366
10,914
20,233
19,658
19,083
18,507
40,254
50,634
48,855
48,855
45,699
96,237
85,464
83,385
81,339
74,428
70,632
69,108
64,985
63,464
58,970
57,341
55,711
54,082
52,453
51,205
51,20552,45354,08255,71157,34158,97063,46464,98569,10870,63274,42881,33983,38585,46496,23745,69948,85548,85550,63440,25418,50719,08319,65820,23310,91411,3668,51610,31210,69611,08111,13112,68013,11713,55410,88511,0039,6419,6998,1468,14608,20000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,657
0
398
0
10,113
10,025
11,501
11,352
13,992
13,524
13,056
11,208
11,323
10,937
10,552
3
5
2
2
2
2
2
2
39
33
10
16
0
465
465
457
774
766
829
821
0
792
772
0
0
0
0
000077279208218297667744574654650161033392222225310,55210,93711,32311,20813,05613,52413,99211,35211,50110,02510,113039808,65700000000000000000000000000000000
> Total Liabilities 
0
0
0
39
39
41
43
40
44
48
50
52
55
55
61
68
84
83
92
53
66
58
66
66
82
82
94
108
115
121
133
153
50
51
55
9,650
2,610
7,951
9,151
4,420
14,258
13,014
11,059
7,395
10,999
14,893
15,828
10,624
7,636
7,855
22,501
22,301
27,634
28,700
57,387
73,250
57,821
57,821
54,049
128,407
128,100
116,229
118,288
107,682
91,531
96,094
95,619
106,304
97,106
100,721
98,396
98,086
90,379
86,005
86,00590,37998,08698,396100,72197,106106,30495,61996,09491,531107,682118,288116,229128,100128,40754,04957,82157,82173,25057,38728,70027,63422,30122,5017,8557,63610,62415,82814,89310,9997,39511,05913,01414,2584,4209,1517,9512,6109,650555150153133121115108948282666658665392838468615555525048444043413939000
   > Total Current Liabilities 
0
0
0
39
39
41
43
40
44
48
50
52
55
55
61
68
84
83
92
53
66
58
66
66
82
82
94
108
115
121
133
153
50
51
55
9,203
1,479
1,778
2,804
3,205
10,104
8,731
6,972
3,354
3,610
3,508
4,801
4,342
3,395
3,587
4,655
4,504
5,373
6,102
15,949
42,033
28,307
28,307
25,813
83,683
109,438
97,997
100,571
80,360
64,442
73,204
67,150
85,416
69,015
65,463
64,187
83,689
62,228
61,252
61,25262,22883,68964,18765,46369,01585,41667,15073,20464,44280,360100,57197,997109,43883,68325,81328,30728,30742,03315,9496,1025,3734,5044,6553,5873,3954,3424,8013,5083,6103,3546,9728,73110,1043,2052,8041,7781,4799,203555150153133121115108948282666658665392838468615555525048444043413939000
       Short-term Debt 
0
0
0
34
34
34
34
34
38
48
49
0
55
55
0
0
78
78
0
59
59
52
0
55
68
68
83
83
96
100
105
113
29
31
32
8,514
0
0
1,292
1,221
276
347
80
0
0
0
0
0
0
0
1,677
0
0
79
83
3,907
1,492
1,283
854
7,032
25,542
22,112
24,725
4,688
3,909
9,012
7,519
13,708
0
1,277
39
25,878
4,252
6,127
6,1274,25225,878391,277013,7087,5199,0123,9094,68824,72522,11225,5427,0328541,2831,4923,9078379001,6770000000803472761,2211,292008,51432312911310510096838368685505259590787800555504948383434343434000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,700
0
0
0
0
0
5,380
0
4,000
0
0
0
0
0
0
0
0
0
0
0
263
4,559
1,492
1,582
753
6,121
24,602
21,028
23,552
3,485
3,909
9,012
7,519
13,708
1,648
1,277
1,065
16,700
4,252
6,127
6,1274,25216,7001,0651,2771,64813,7087,5199,0123,9093,48523,55221,02824,6026,1217531,5821,4924,559263000000000004,00005,380000005,7000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
2
2
3
0
6
0
0
0
0
0
4
3
0
0
3
0
1
0
4
4
0
6
12
14
121
7
13
11
3
0
4
546
1,197
1,075
1,076
1,177
3,520
2,508
2,446
1,409
2,220
1,661
3,415
3,199
2,120
2,112
2,372
2,131
2,297
2,633
9,599
6,956
22,792
11,825
7,157
16,529
19,255
9,383
15,604
11,130
10,987
14,667
10,580
14,673
13,478
14,466
10,473
10,475
10,440
13,513
13,51310,44010,47510,47314,46613,47814,67310,58014,66710,98711,13015,6049,38319,25516,5297,15711,82522,7926,9569,5992,6332,2972,1312,3722,1122,1203,1993,4151,6612,2201,4092,4462,5083,5201,1771,0761,0751,19754640311137121141260440103003400000603220000
       Other Current Liabilities 
0
0
0
4
4
5
6
6
1
1
0
52
55
1
57
65
84
5
90
53
7
6
62
62
0
8
11
94
0
14
29
142
18
19
-66
57
197
617
1,642
1,943
6,585
6,223
4,526
1,945
1,390
1,847
1,386
1,143
1,275
1,475
593
2,373
3,075
3,311
3,367
30,990
2,193
14,860
17,327
7,087
7,407
7,360
4,516
64,442
49,546
49,425
48,951
57,035
28,606
8,990
53,675
47,336
47,536
41,612
41,61247,53647,33653,6758,99028,60657,03548,95149,42549,54664,4424,5167,3607,4077,08717,32714,8602,19330,9903,3673,3113,0752,3735931,4751,2751,1431,3861,8471,3901,9454,5266,2236,5851,9431,64261719757-66191814229140941180626267539058465571555201166544000
   > Long-term Liabilities 
0
0
0
0
34
36
34
34
44
48
0
0
0
55
3
3
0
78
3
0
59
53
0
60
0
74
97
104
0
106
124
124
32
31
447
447
1,131
6,173
6,347
1,215
4,153
4,283
4,088
4,041
7,388
11,385
11,027
6,282
4,241
4,267
17,846
17,797
22,261
22,598
41,438
31,217
29,514
29,514
28,236
44,724
18,662
18,232
17,717
27,322
27,089
22,890
28,469
20,888
28,091
35,258
34,209
14,397
28,151
24,753
24,75328,15114,39734,20935,25828,09120,88828,46922,89027,08927,32217,71718,23218,66244,72428,23629,51429,51431,21741,43822,59822,26117,79717,8464,2674,2416,28211,02711,3857,3884,0414,0884,2834,1531,2156,3476,1731,131447447313212412410601049774060053590378033550004844343436340000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,825
0
0
0
0
0
0
0
0
0
0
0
0
5,036
5,135
0
0
23,395
8,162
11,171
10,680
9,946
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000009,94610,68011,1718,16223,395005,1355,0360000000000004,8250000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
512
0
469
0
1,091
1,253
1,425
1,205
4,153
4,283
4,087
4,041
7,389
11,385
11,026
6,282
4,241
4,267
12,810
12,662
22,261
22,283
41,146
30,413
28,789
28,465
28,025
24,922
15,858
15,320
14,872
10,749
12,810
9,330
12,465
0
13,378
20,415
0
0
0
0
000020,41513,378012,4659,33012,81010,74914,87215,32015,85824,92228,02528,46528,78930,41341,14622,28322,26112,66212,8104,2674,2416,28211,02611,3857,3894,0414,0874,2834,1531,2051,4251,2531,0910469051200000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396
447
467
613
0
0
213
0
5
3
1
3,818
3,300
120
94
47
26
29
13
11
11
11
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001111111113292647941203,3003,8181350213006134674473960000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
29
29
19
64
55
38
26
0
-10
-12
-14
-32
-42
-48
-56
-67
-24
-38
-36
-49
-49
0
-70
-82
-95
-111
-111
-126
-148
-36
-45
-44
551
15,616
13,409
15,259
17,566
10,085
7,187
10,447
8,521
4,000
6,353
3,031
12,750
13,425
10,130
19,898
16,037
7,088
2,324
17,090
85,704
95,015
95,015
112,693
143,150
137,568
111,500
105,536
61,144
46,092
53,906
45,817
40,912
39,357
32,167
32,853
30,777
27,716
29,826
29,82627,71630,77732,85332,16739,35740,91245,81753,90646,09261,144105,536111,500137,568143,150112,69395,01595,01585,70417,0902,3247,08816,03719,89810,13013,42512,7503,0316,3534,0008,52110,4477,18710,08517,56615,25913,40915,616551-44-45-36-148-126-111-111-95-82-700-49-49-36-38-24-67-56-48-42-32-14-12-10026385564192929000
   Common Stock
0
0
0
0
0
0
0
0
205
205
0
0
0
0
0
0
0
1
0
0
0
395
0
2
0
407
412
412
414
414
417
417
540
540
555
4
1
1
1
2
0
1
1
1
0
0
0
4
0
0
1
1
2
2
2
10
13
13
2
2
3
3
3
3
4
6
0
0
1
1
1
1
1
1
1111110064333322131310222110040001110211145555405404174174144144124124070203950001000000020520500000000
   Retained Earnings Total Equity00000000000000-159,301-133,841-124,316-120,010-116,865-111,533-111,319-106,390-91,858-87,362-82,704-79,258-79,805-76,987-73,315-69,070-62,319-57,103-52,286-46,561-31,264-23,990-20,658-18,381-12,610-656-6460-619-607-585-569000000-1000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
1
1
1
0
-23
-1
-1
-1
-1
-1
0
-314
0
0
-47
-451
-481
-481
-53
-511
-531
0
-58
-58
0
0
-63
-63
-53
-53
-5,000
-5,000
-79
-97
-112
-130
-157
-184
-246
-326
-407
-498
-540
-350
-366
-381
-396
-412
-428
0
-484
0
-504
302,451
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000302,451-5040-4840-428-412-396-381-366-350-540-498-407-326-246-184-157-130-112-97-79-5,000-5,000-53-53-63-6300-58-580-531-511-53-481-481-451-4700-3140-1-1-1-1-1-230111000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
0
0
0
0
0
0
41
42
43
43
0
47
48
13,157
38,996
39,065
39,247
48,827
56,646
59,472
67,549
70,839
73,069
79,667
80,018
92,552
92,682
92,834
107,258
107,893
113,475
113,640
128,620
202,558
215,013
215,366
246,532
302,448
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000302,448246,532215,366215,013202,558128,620113,640113,475107,893107,25892,83492,68292,55280,01879,66773,06970,83967,54959,47256,64648,82739,24739,06538,99613,157484704343424100000029000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
155
155
157
218
219
220
16
0
225
232
242
243
245
253
258
265
335
342
416
432
431
0
35
37
38
3
102
42
43
43
109
100
13,157
38,996
39,065
39,326
48,924
56,758
59,602
67,706
71,023
73,315
79,993
80,425
93,050
93,222
93,184
107,624
108,274
113,871
114,052
129,048
202,558
0
215,013
246,532
-2
315,864
317,647
323,231
331,912
334,560
345,253
340,289
342,584
0
344,415
345,321
346,132
347,688
348,324
348,324347,688346,132345,321344,4150342,584340,289345,253334,560331,912323,231317,647315,864-2246,532215,0130202,558129,048114,052113,871108,274107,62493,18493,22293,05080,42579,99373,31571,02367,70659,60256,75848,92439,32639,06538,99613,15710010943434210233837350431432416342335265258253245243242232225016220219218157155155000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.